Vident Advisory, LLC Vertex Pharmaceuticals Inc Transaction History
Vident Advisory, LLC
- $4.8 Trillion
- Q1 2024
A detailed history of Vident Advisory, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Vident Advisory, LLC holds 51,527 shares of VRTX stock, worth $24.2 Million. This represents 0.45% of its overall portfolio holdings.
Number of Shares
51,527
Previous 44,180
16.63%
Holding current value
$24.2 Million
Previous $18 Billion
19.82%
% of portfolio
0.45%
Previous 0.45%
Shares
4 transactions
Others Institutions Holding VRTX
# of Institutions
1,624Shares Held
222MCall Options Held
1.35MPut Options Held
1.49M-
Capital World Investors Los Angeles, CA25.6MShares$12 Billion1.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA22.7MShares$10.7 Billion0.19% of portfolio
-
Black Rock Inc. New York, NY22MShares$10.3 Billion0.22% of portfolio
-
State Street Corp Boston, MA12MShares$5.65 Billion0.23% of portfolio
-
Alliancebernstein L.P. New York, NY7.1MShares$3.34 Billion1.08% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $121B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...